The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

At the end of the treatment evaluation, they also looked at progression ... and dexamethasone for transplantation-eligible ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.